MarketCap
Facebook
X
Telegram
GBS Revenue | GBS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue GBS
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.22 M | 3.05 M | 3.11 M | 1.26 M | 437 K | 1.98 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.22 M | 437 K | 2.34 M |
Quarterly Revenue GBS
| 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.06 M | 897 K | 1.11 M | 897 K | 1.11 M | - | 902 K | 607 K | 872 K | - | 908 K | 917 K | 906 K | - | 457 K | 357 K | - | 357 K | 192 K | 178 K | 373 K | 178 K | 34.3 K | 283 K | 55.4 K | 283 K | -1.53 K | -798 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.11 M | -1.53 K | 539 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abbott Laboratories
ABT
|
44.3 B | $ 100.1 | 2.67 % | $ 174 B |  USA |
 |
Aethlon Medical
AEMD
|
574 K | $ 6.53 | 1.16 % | $ 4.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
3.24 B | $ 5.74 | 2.5 % | $ 776 M | USA |
 |
Align Technology
ALGN
|
4.03 B | $ 140.65 | 0.1 % | $ 10.2 B | USA |
 |
Apyx Medical Corporation
APYX
|
52.8 M | $ 2.6 | 1.96 % | $ 107 M | USA |
 |
Accuray Incorporated
ARAY
|
402 M | $ 0.3 | 7.37 % | $ 36.8 M | USA |
 |
Alphatec Holdings
ATEC
|
764 M | $ 10.72 | 6.88 % | $ 1.61 B | USA |
 |
AxoGen
AXGN
|
225 M | $ 37.22 | 0.21 % | $ 1.71 B | USA |
 |
Butterfly Network
BFLY
|
97.6 M | $ 9.38 | 4.8 % | $ 2.32 B | USA |
 |
Bio-Rad Laboratories
BIO
|
2.58 B | $ 379.82 | 2.89 % | $ 10.4 B | USA |
 |
Bruker Corporation
BRKR
|
3.44 B | $ 63.86 | 0.98 % | $ 9.69 B | USA |
 |
Boston Scientific Corporation
BSX
|
20.1 B | $ 42.4 | 0.31 % | $ 62.8 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
400 M | $ 8.77 | 0.34 % | $ 639 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
37 M | $ 11.52 | 5.74 % | $ 326 M | USA |
 |
CONMED Corporation
CNMD
|
1.37 B | $ 47.33 | 2.25 % | $ 1.47 B | USA |
 |
Cytosorbents Corporation
CTSO
|
37.1 M | $ 3.97 | 0.12 % | $ 247 M | USA |
 |
Delcath Systems
DCTH
|
85.2 M | $ 15.87 | 4.89 % | $ 568 M | USA |
 |
Electromed
ELMD
|
73.8 M | $ 28.32 | 0.78 % | $ 234 M | USA |
 |
Establishment Labs Holdings
ESTA
|
211 M | $ 66.47 | 3.76 % | $ 1.97 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 87.23 | 2.44 % | $ 51 B | USA |
 |
Globus Medical
GMED
|
2.94 B | $ 76.57 | 1.28 % | $ 10.4 B | USA |
 |
Helius Medical Technologies
HSDT
|
6.02 M | $ 2.65 | 0.76 % | $ 58.4 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
1.64 B | $ 13.29 | 4.81 % | $ 1.02 B | USA |
 |
Inogen
INGN
|
349 M | $ 5.94 | 0.34 % | $ 158 M | USA |
 |
InMode Ltd.
INMD
|
370 M | $ 14.13 | 0.28 % | $ 913 M | Israel |
 |
Inspire Medical Systems
INSP
|
912 M | $ 70.75 | 1.11 % | $ 2.08 B | USA |
 |
IRIDEX Corporation
IRIX
|
52.7 M | $ 0.69 | 7.28 % | $ 11.7 M | USA |
 |
IRadimed Corporation
IRMD
|
83.8 M | $ 86.47 | 1.25 % | $ 1.1 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.85 B | $ 126.45 | 0.1 % | $ 4.39 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
236 M | $ 22.89 | 3.29 % | $ 537 M | USA |
 |
LivaNova PLC
LIVN
|
1.39 B | $ 76.43 | 1.81 % | $ 4.17 B |  Britain |
|
LENSAR
LNSR
|
58.4 M | $ 6.67 | 0.59 % | $ 79.8 M | USA |
 |
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.88 | 2.73 % | $ 76.5 M | USA |
 |
Medtronic PLC
MDT
|
36.4 B | $ 87.97 | 1.88 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
419 M | $ 4.55 | 0.54 % | $ 672 M | USA |
 |
Myomo
MYO
|
40.9 M | $ 1.67 | 2.45 % | $ 69.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
13 M | $ 0.64 | 1.15 % | $ 41.5 M | Israel |
 |
InspireMD
NSPR
|
8.98 M | $ 0.58 | 1.64 % | $ 37.3 M | Israel |
 |
Orthofix Medical
OFIX
|
822 M | $ 9.5 | 4.51 % | $ 376 M |  Curacao |
 |
Outset Medical
OM
|
119 M | $ 4.1 | 3.54 % | $ 62.4 K | USA |
 |
PAVmed
PAVM
|
71 K | $ 2.66 | 4.36 % | $ 1.78 M | USA |
 |
Penumbra
PEN
|
1.4 B | $ 317.11 | 0.07 % | $ 12.3 B | USA |
 |
Insulet Corporation
PODD
|
2.71 B | $ 135.62 | 2.98 % | $ 9.54 B | USA |
 |
Profound Medical Corp.
PROF
|
16.1 M | $ 6.03 | 3.25 % | $ 182 M |  Canada |
 |
Quanterix Corporation
QTRX
|
139 M | $ 3.81 | 4.67 % | $ 162 M | USA |
 |
AVITA Medical
RCEL
|
71.6 M | $ 13.25 | 4.17 % | $ 369 M |  Australia |
 |
Sintx Technologies
SINT
|
1.02 M | $ 2.18 | 1.05 % | $ 6.05 M | USA |
 |
Smith & Nephew plc
SNN
|
4.56 B | $ 26.92 | 1.87 % | $ 23.3 B | Britain |
 |
Sensus Healthcare
SRTS
|
27.5 M | $ 2.92 | 0.34 % | $ 47.7 M | USA |
 |
Stryker Corporation
SYK
|
7.17 B | $ 285.22 | 3.54 % | $ 109 B | USA |